Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	13.43B
Revenue (ttm)	933.81M
Net Income (ttm)	367.25M
Shares Out	79.92M
EPS (ttm)	4.55
PE Ratio	36.92
Forward PE	31.46
Dividend	5.12 (3.05%)
Ex-Dividend Date	Apr 30, 2025

Volume	134,839
Average Volume	309,308
Open	168.00
Previous Close	168.00
Day's Range	166.50 - 169.00
52-Week Range	143.50 - 215.00
Beta	0.36
RSI	49.55
Earnings Date	Mar 28, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2024, TPEX:6712's revenue was 933.81 million, an increase of 23.13% compared to the previous year's 758.39 million. Earnings were 367.25 million, a decrease of -31.91%.